Why You Should Attend

Have a question about this event?
Customer Service representatives are available to help from 8 AM - 6 PM EST
Call 888-670-8200

Need Technical Assistance With this Website?
Send an email to IIR's Web Department

BioAnalytical Method Development

October 06 - 08, 2008 | InterContinental San Francisco, San Francisco, CA

FDA discusses the challenges faced during regulatory review of Antibody-Drug Conjugates
Gain new insights on how to apply molecular interaction information to aid drug discovery and development
Learn reliable methods to compare binding properties of antibody derivatives
Use molecular interaction analyses to accelerate identification of high potential therapeutic antibody candidates
Determine the latest emerging developments in label-free detection systems
Compare PK assay formats and improve accuracy on drug measurement
Assay development principles and technical approaches are revealed
ADC technologies – ELISA PK assay considerations, compare in vivo vs. in vitro stability, mass spectrometric-based ADC strategies
How does in vitro Fc functionality data relate to in vivo activity, efficacy, and safety?
Fc effector functions - biology, strategies, challenges, and methodologies